HPGC(SH:600664) Ge Long Hui·2025-09-03 09:43Core Viewpoint - The company is transitioning its strategy from a focus on generic drugs to a greater emphasis on innovative drug development, aiming to enhance its product line and explore new research paths [1] Group 1 - The company has established a short, medium, and long-term research and development plan [1] - The strategic shift involves moving from "combination of generics and innovation, with a focus on generics" to "combination of generics and innovation, with a focus on innovation" [1] - The company is actively exploring new paths for product research and development [1] Group 2 - There are ongoing research and development projects for innovative drugs [1] - The company is assessing the feasibility of launching innovative drug research projects across multiple fields, including cardiovascular, metabolic, respiratory, anti-infection, and anti-tumor areas [1]